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Abstract
The Warburg Effect is characterized by an irreversible injury to mitochondrial oxidative phosphorylation (OXPHOS) and an
increased rate of aerobic glycolysis. In this study, we utilized a breast epithelial cell line lacking mitochondrial DNA (rho
0)
that exhibits the Warburg Effect associated with breast cancer. We developed a MitoExpress array for rapid analysis of all
known nuclear genes encoding the mitochondrial proteome. The gene-expression pattern was compared among a normal
breast epithelial cell line, its rho
0 derivative, breast cancer cell lines and primary breast tumors. Among several genes, our
study revealed that over-expression of mitochondrial uncoupling protein UCP2 in rho
0 breast epithelial cells reflects gene
expression changes in breast cancer cell lines and in primary breast tumors. Furthermore, over-expression of UCP2 was also
found in leukemia, ovarian, bladder, esophagus, testicular, colorectal, kidney, pancreatic, lung and prostate tumors. Ectopic
expression of UCP2 in MCF7 breast cancer cells led to a decreased mitochondrial membrane potential and increased
tumorigenic properties as measured by cell migration, in vitro invasion and anchorage independent growth. Consistent
with in vitro studies, we demonstrate that UCP2 over-expression leads to development of tumors in vivo in an orthotopic
model of breast cancer. Genipin, a plant derived small molecule, suppressed the UCP2 led tumorigenic properties, which
were mediated by decreased reactive oxygen species and down-regulation of UCP2. However, UCP1, 3, 4 and 5 gene
expression was unaffected. UCP2 transcription was controlled by SMAD4. Together, these studies suggest a tumor-
promoting function of UCP2 in breast cancer. In summary, our studies demonstrate that i) the Warburg Effect is mediated by
UCP2; ii) UCP2 is over-expressed in breast and many other cancers; iii) UCP2 promotes tumorigenic properties in vitro and in
vivo and iv) genipin suppresses the tumor promoting function of UCP2.
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Introduction
Mitochondria play a central role in the cell growth, metabolism
and cell death. Mitochondria produce energy by oxidative
phosphorylation (OXPHOS) and are involved in the metabolism
of fatty acids, nucleotides, amino acids and carbohydrates; synthesis
of heme, Fe-S, ubiquinone and cofactors; DNA replication, repair
and methylation; and antibacterial defense [1,2,3,4]. Since
mitochondria perform multiple cellular functions, defective mito-
chondria contribute to a vast number of human diseases [5,6,7,8].
Otto Warburg in 1956 proposed that cancer was caused by
defects in mitochondria, forcing cells to shift to energy production
through glycolysis despite aerobic conditions [9]. This character-
istic of cancers is described as the ‘‘Warburg Effect.’’ The Warburg
Effect plays an important role in tumor development by
remodeling the metabolic profile, which allows tumor cell survival
under adverse conditions [10,11,12,13,14]. Warburg stated that
cancer cells originate in two phases: i) ‘‘The first phase is the
irreversible injury to respiration (OXPHOS).’’ ii) ‘‘The irreversible
injury to respiration (OXPHOS) is followed, by a long struggle for
existence by the injured cells to maintain their structure, in which
a part of the cells perish (apoptosis) for lack of energy, while
another part succeed in replacing the lost respiration energy by
aerobic glycolysis’’ [9]. Our studies and those conducted by others
suggest that the underlying cause of ‘‘irreversible injury’’ to
OXPHOS includes reduced mtDNA content and mutations in
mtDNA and in nuclear genes affecting OXPHOS [15,16,17,18].
Our previous studies have also revealed that defects in OXPHOS
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changes in the nuclear genome [3,19,20,21]. We reported an
undetectable level of mtDNA-encoded cytochrome c-oxidase
subunit II in more than 40% of breast and ovarian tumors,
suggesting a significant depletion of mtDNA in primary tumors
[22,23]. Other laboratories have also described a decrease in
mtDNA content in breast [24,25], renal [26], hepatocellular [27],
gastric [28] and prostate tumors [16]. Depletion of mtDNA is also
proportional to a decrease in OXPHOS levels in renal tumors
[29]. A reduced mtDNA copy number is also associated with
resistance to apoptosis and increased metastasis [30,31,32].
We recently developed a breast epithelial cell line devoid of
mitochondrial DNA (rho
0) that recapitulates the Warburg Effect
[33] and mimics depletion of mtDNA in the variety of cancers
described above. The rho
0 cells lack mtDNA and thus lack the
critical subunits of the respiratory chain, causing irreversible injury
to respiration and forcing the cells to utilize aerobic glycolysis for
ATP production [33,34,35]. The rho
0 cells exhibiting the
Warburg Effect serve as a valuable tool for identifying genomic
and epigenomic changes associated with tumorigenesis [33,36]. In
this paper, we determined whether the gene expression changes
associated with rho
0 state in epithelial cells reflect changes in
cancer cell lines and in primary tumors. Among many genes, we
confirmed that UCP2 was over-expressed in rho
0 epithelial cells,
breast cancer cell lines and primary breast tumors. UCP2 is a
member of the family of uncoupling proteins located in the inner
mitochondrial membrane [37]. UCP2 function is linked to obesity
and diabetes [38]. The role of UCP2 in cancers is not well
understood. This paper describes the tumor promoting properties
of UCP2 in vitro and in vivo in a mouse xenograft model. We also
describe that genipin, a small molecule extracted from the
gardenia plant, reduces the tumor promoting properties induced
by over-expression of UCP2.
Materials and Methods
MitoExpress array design
All proteins related to mitochondrial structure, function and
dynamics were extracted from the published literature
[2,39,40,41,42] and from various public databases, such as the
Human Mitochondrial Protein Database, Mitomap, Mitop2,
Migenes and Mitoproteome. Human orthologs from the mito-
chondrial proteins of lower organisms were also extracted from the
NCBI, and redundant genes were carefully removed. The
corresponding probe sets of genes were selected from NetAffx.
The extracted mitochondrial proteins were made into a single list
and then filtered to get rid of redundancy. Probe sets correspond-
ing to mitochondrial proteins selected for analysis were identified
from the list of human expression chip HG-U133. Probe sets of the
mitochondrial genes, along with the standard human normaliza-
tion probes, were tiled on a chip using a unique combination of
photolithography and combinatorial chemistry in the 11 micron,
100–2187 affymetrix array format. The final set of genes (1,136
genes) tiled on the mitochondrial expression chip is given in
Table S1.
Cell culture
All the cell lines were purchased from ATCC (Manassas, VA).
The breast epithelial cells (MCF12A) were grown in media
consisting of Ham’s F12/Dulbecco’s Modified Eagle’s Media
(DMEM-F12; Cellgro, Herndon, VA) containing 100 U/ml
penicillin and 100 mg/ml streptomycin (Invitrogen, Carlsbad,
CA), 100 ng/ml cholera toxin (Invitrogen), 0.5 mg/ml hydrocor-
tisone (Sigma, St Louis, MO), 10 mg/ml insulin (Sigma), 20 ng/ml
EGF (Sigma) and 10% horse serum (Invitrogen); the mtDNA-
compromised breast epithelial cell line (MCF12A rho
0) was
cultured in MCF12A medium with 50 mg/ml uridine (Sigma),
and breast cancer cell lines (MCF7, MDAMB231, MDAMB435)
were grown in Dulbecco’s Modified Eagle’s Media (DMEM;
Cellgro) supplemented with 10% fetal bovine serum (FBS;
Cellgro), 100 U/ml penicillin and 100 mg/ml streptomycin. Cells
were maintained in a 37uC, 5% CO2 environment. Mouse
mammary epithelial NMuMG cells were cultured at 37uC under
an atmosphere of 5% CO2 in DMEM supplemented with 10%
FBS (Cellgro) and 10 mg/ml insulin.
Transfection and selection of stable cell lines
The UCP2 cDNA was kindly provided by Dr. Mills. The
plasmid was transfected into MCF7 cells with Fugene HD
transfection reagent (Roche, Fishers, IN) and stably transfected
cells were selected for after 48 hrs with medium containing G418
(2 mg/ml). UCP2 over-expression was confirmed by Western blot
analysis. For the Smad4 silencing, NMuMG cells were transfected
with siRNA duplexes to Smad4 (Dharmacon Inc., Lafayette, CO)
and scramble control siRNA labeled with rhodamine (Qiagen,
Valencia, CA) using Oligofectamine reagents (Invitrogen). The
silencing of Smad4 was confirmed by mouse monoclonal
antibodies to Smad2/3 and Smad4 (BD Biosciences, Palo Alto,
CA).
RNA isolation and cDNA synthesis
Total RNA was isolated from human breast cell lines and mouse
NMuMG cells using the Trizol method (Invitrogen) and further
purified by RNeasy Midi Columns (Qiagen). The RNA was
quantified by Nanodrop (Nanodrop Technologies, Wilmington,
DE), and quality was checked by O.D. at 260 nm. The primary
breast tumor RNA was obtained from the Pathology Core Facility
at Roswell Park Cancer Institute. cDNA was synthesized with a
SuperScript III First Strand Synthesis kit, using the standard
protocol (Invitrogen). For microarray experiments, the cDNA was
synthesized according the manufacturer’s guidelines.
Gene-expression analysis
7 mg of total RNA was used for the synthesis of double-stranded
cDNA with the Genechip tiling WT double-stranded cDNA
synthesis kit (Affymetrix, Santa Clara, CA). After the cDNA
synthesis, the samples were cleaned up by the sample clean-up
module and used for chip analysis and real-time PCR confirma-
tion. The doubled-stranded DNA was fragmented and labeled
with a Genechip WT double-stranded DNA terminal labeling kit.
The labeled DNA was hybridized along with the control
oligonucleotide B2 to the arrays. The arrays were then washed
and stained according to the manufacturer’s protocol. The arrays
were scanned by the Affymetrix scanner and viewed by the
microarray suite. The data was exported to Array Assist
(Stratagene) and analyzed. We used the PLIER algorithm to
normalize the data and generate raw signal values. Background
noise was filtered out by using the detection above background.
Once the raw signal values were generated, they were filtered for
genes that were $two-fold and had a p-value #0.05. A principal
component analysis was done to ensure that samples clustered
correctly. All data is MIAME compliant and the raw data has been
deposited in a MIAME-compliant database GEO, as detailed by
the MGED Society.
A mouse microarray analysis was performed using Affymetrix
MOE430_2AB chips. Total RNA samples were isolated from
NMuMG cells transfected with siRNA control or siSmad4
duplexes, following treatment with 2 ng/ml TGF-b1 (R&D
Tumor Promoting UCP2
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expression data in CEL format was processed and converted to
numeric data by the gcRMA method using the ExpressionFile-
Creator module of the GenePattern package [43], during which
quantile normalization and computation of ‘‘present’’ and
‘‘absent’’ calls were included. To identify differentially expressed
genes, we used criteria requiring a minimal of a twofold change
between the compared experiments and a probe showing higher
expression to have a minimal value of 75 and shown as ‘‘present.’’
The latter two parameters reduced false positives resulting from
low expression and/or inconsistent probe measurements. The
probes showing up- and down-regulation in response to TGF-b
treatment were collected from NMuMG and siSmad4-transfected
cells. Overlaps between the lists were identified by in-house PERL
scripts. The function classification and statistical over-representa-
tion of gene-function categories (e.g., gene ontology terms) were
analyzed using the DAVID package [44].
Confirmation of differentially expressed genes
Among the differentially expressed genes, highly up- and down-
regulated genes were selected for validation based on their
relevance to mitochondrial structure and function. Confirmation
of the differential expression was done by Superarray RT-PCR
plates (SA Biosciences, Frederick, MD). The optimized primers for
the selected genes were coated to the custom-made 96-well plate
PCR array. Quantitative real-time PCR assays were performed
using ABI Prism 7900 (Applied Biosystems, Foster City, CA) with
SYBR GreenER PCR Master Mix (Invitrogen), according to the
manufacturer’s protocol. The data was analyzed by RQ Manager
(Applied Biosystems) software, and the relative gene expression of
the genes was analyzed by comparing results to the housekeeping
gene (b-actin) using the Delta delta Ct method.
Western blot analysis of proteins
Western blot was used to check the over-expression of UCP2
protein. The whole cell extract was prepared using the standard
methods, and 100 mg of protein was loaded and resolved on 12%
SDS-PAGE. The separated proteins were transferred to an
Immuno-Blot PVDF Membrane (Millipore, Billerica, MA),
followed by incubation for one hour at room temperature with
5% milk to block nonspecific binding. Blots were incubated
overnight at 4uC with 1:300 UCP2 (Santa Cruz Biotechnology,
Santa Cruz, CA) antibody, followed by washing and incubation
with a 1:5000 anti-goat IgG antibody (Vector Laboratories,
Burlingame, CA). The bound secondary antibody was detected
using an enhanced chemiluminescence solution. The membranes
were exposed to CL-XPosure film (ThermoScientific, Rockford,
IL). Anti-mouse Complex III core 2 subunit antibody (Molecular
Probes, Eugene, OR) was used to determine equal protein-
loading.
Immunohistochemistry
All experiments were approved by the Roswell Park Cancer
Institute Institutional Review Board, permit number I92106. A
tissue-array slide from the Cooperative Human Tissue Network
(CHTN) and Tissue Array Research Program (TARP5) of the
National Cancer Institute, National Institutes of Health, Bethesda,
MD, was also used in the present study. Consent from patients was
not needed, as anonymous tissue samples were used for study.
These samples were collected by the biorepository resource facility
of the Roswell Park Cancer Institute and provided to us under
IRB-approved permit number I92106. The slide contained breast
and ovarian carcinomas as well as multiple benign tissues from
different organs. One section from a formalin-fixed, paraffin-
embedded benign spleen was used as a positive control.
Characterization of the lesions and grading of the tumors was
done by a pathologist, as previously described [23]. The
immunohistochemistry protocol, as described by Desouki et al.,
2005 [23], was applied with modifications. Briefly, the slides were
de-paraffinized by incubation in xylene and ascending grades of
alcohol. Antigen retrieval was done by heating in a citrate-based,
antigen-unmasking solution (Vector Laboratories, Burlingame,
CA, cat. no. H-3300) for 30 min at 98uC, incubated in 3%
hydrogen peroxide (H2O2) for 10 min, blocked with blocking
peptide for 30 min, incubated with 8 mg/ml anti-UCP1 (Abnova,
Walnut, CA) and anti-UCP2 (Santa Cruz Biotech, Santa Cruz,
CA, cat # sc-6525) antibody for 1 h at room temperature,
followed by incubation with biotinylated secondary anti-rabbit and
anti-goat solution for 30 min, respectively, and another 30 min
with Vectastatin ABC kit (Vector Laboratories, Burlingame, CA).
The color was developed by incubating slides with peroxidase
substrate solution, followed by counterstaining with Hematoxylin.
The sections were also incubated with secondary antibody only to
check nonspecific bindings. All sections were examined with an
Olympus BX50 microscope, and pictures were taken with an
Olympus DP 70 connected to DP Controller software (Olympus,
Center Valley, PA).
An Epi-Info software program, version 3.5.1, was used for
statistical analysis. A linear correlation test was performed to
determine the correlation between tumor grades and UCP2
immunoreactivity. Scoring of immunoreactivity was considered to
be negative or positive, with the same parameters described above
(score + ,10% positive, score ++ 10–50% positive and score +++
.50% positive) [23]. Grades and IHC scores were considered
nominal to calculate the correlation coefficient.
Mitochondrial membrane potential and ATP
measurements
Mitochondrial membrane potential was measured by the
fluorescence of tetramethylrhodamine, ethyl ester (TMRE,
Molecular Probes, Eugene, OR). Cells were incubated with
100 nM TMRE for 35 min, harvested and resusupended in PBS.
The fluorescence of the cells was read on the FL2 channel of a
Becton Dickinson FACScan Flow Cytometer (Franklin Lakes, NJ)
[45]. Intracellular ATP levels were measured using the ATP
bioluminescent assay kit (Sigma) according to the manufacturer’s
protocol.
MTT assay
Cell viability and proliferation were measured by rinsing the
cells with PBS, then incubating them with 833 mg/ml of 3-(4,5-
dimethlythiazol-2-yl)-2,-diaphenyltetrazolium bromide (MTT)
(Molecular Probes) for 3 h. MTT formazan crystals were dissolved
in an isopropanol solution containing 4 mM HCl and 0.1%
Nonidet P-40. The absorbance of the reduced purple formazan
was measured at 590 nm with a reference wavelength of 620 nm
[46].
Wound-healing
Cell migration was measured by a wound-healing scratch assay.
Scratches were made in a confluent monolayer of cells with a
sterile pipette tip and immediately photographed. Migration of
cells into the scratch was monitored for up to 24 h [47].
Matrigel invasion
In vitro invasion of cells was measured by Matrigel invasion
using a Matrigel Boyden chamber (BD Biosciences, Bedford, MA).
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chamber in DMEM with 0.1% BSA. NIH-3T3-conditioned media
containing 10% FBS was added to the bottom as a chemo-
attractant. Cells were allowed to migrate for 24 h, and then the
membrane was stained with a Diff-Quik Stain Set (Dade Behring,
Newark, DE) [18]. Cells were also plated in control inserts without
any matrigel (BD Biosciences) to control for toxicity and adhesion
to the membrane.
Soft-agar assay
Anchorage-independent growth was measured by a colony
formation in soft-agar. Cells were mixed with 0.3% agarose and
plated on dishes containing 0.5% agarose. Growth media was
added to each well and replenished every 3 to 4 days. Colonies
were visualized by staining with 0.005% crystal violet for 1 h [48].
Orthotopic tumor growth of MCF-7 and MCF-7-UCP2
cells
Female athymic nude mice were obtained at 4-6 weeks of age
from Harlan Laboratories (Indianapolis, IN). 17b-estradiol pellets
(NE-121, 1.7 mg, 90 day release, Innovative Research of America,
Sarasota, FL), were implanted subcutaneously two days prior to
tumor cell injection. Orthotopic breast cancer xenografts were
established by implanting 1610
7 MCF-7 or MCF-7-UCP2 cells in
a 1:1 mixture with Matrigel (BD Biosciences, San Jose, CA) into
the mammary fat pad in groups of 10 mice each. Tumor growth
was monitored twice weekly by measuring tumor diameter in the
two largest dimensions with calipers. Mean tumor size was
calculated from the product of individual tumor diameters and
reported relative to tumor size at day 3 post-tumor cell injection.
All studies were conducted in accordance with University of
Alabama at Birmingham Institutional Animal Care and Use
Committee regulations.
Clonogenic survival
Reproductive viability was assayed by clonogenic survival. Cells
were harvested after treatment and plated at a low density.
Colonies were allowed to grow for two weeks and were then fixed
with 70% ethanol and stained with 0.1% Coomassie brilliant blue
stain (BioRad).
Reactive oxygen species measurement
Cells were analyzed for reactive oxygen species (ROS)
production by labeling with 10 mM dihydroethidium (DHE)
(Molecular Probes) for 40 min. Oxidation of DHE was analyzed
on a FACSCalibur flow cytometer (Becton Dickinson). 10,000
events were collected for each sample. ROS levels were expressed
as mean fluorescence intensity (MFI), which was calculated by
WinList software (Verity Software House).
Genipin treatment
Genipin is a chemical compound that has been documented
to inhibit UCP2 expression and activity. MCF12A, MCF7 and
UCP2 over-expressing cells were plated in 96-well plates and
treated with varying doses of genipin (0–50 mM) for 48 h, and the
cell viability was analyzed by MTT assay, as described above. For
all other assays, cells were treated with 0, 5 and 10 uM genipin. A
clonogenic survival assay was done to study the effect of genipin on
the survival of the UCP2 over-expressing cells. A RT PCR was
done to check whether any other member of the UCP family was
affected by the genipin treatment. The functional significance of
genipin on the UCP2 over-expressing cells was studied by a
wound-healing, matrigel invasion. DHE oxidation of the MCF7
cells was also analyzed to see the impact of genipin treatment.
In silico analysis
UCP2 expression was checked with the Oncomine database
[49]. The higher expression of UCP2 was analyzed between the
normal and corresponding tumors. Similarly, UCP2 was analyzed
among multiple cancers, such as bladder, colorectum, kidney,
liver, lung, ovarian, pancreatic and prostate cancers.
Results
MitoExpress analyses
We developed an oligonucleotide array named MitoExpress,
contracted through Affymetrix, Inc., to study the differential
expression of the nuclear genes encoding the mitochondrial
proteome in breast epithelial cells, its rho
0 derivative and primary
breast cancer cells. MitoExpress contains 1,136 nuclear genes
encoding mitochondrial proteins that were extracted from various
databases and published literature and then filtered to remove
redundant genes (Table S1). It also contains standard probe sets
for 146 housekeeping genes, the same as that of human expression
chip HG-U133 for normalization and background correction.
Gene-expression similarity in rho
0 breast epithelial and
breast cancer cell lines
Our previous study suggests that depletion of mitochondrial
DNA in breast epithelial cells leads to tumorigenic transformation
in vivo [33]. We hypothesized that the pattern of gene expression
changes in rho
0 breast epithelial cells may help identify novel
tumor-suppressor and oncogenes associated with irreversible
injury to OXPHOS, as described by Warburg [50]. Using the
MitoExpress array, we therefore analyzed gene-expression chang-
es in the MCF12A parental breast epithelial cell line and its rho
0
derivative. The changes in gene expression that were observed in
the rho
0 cells were compared to expression in the breast cancer cell
lines. The gene expression that was twofold or lower compared to
the parental MCF12A rho
+ cell line was considered to be down-
regulated. We found that a total of 29 genes were down-regulated
in both the rho
0 and breast cancer cell lines (Table S2). The gene
expression that was twofold or higher compared to the parental
MCF12A cell line was considered to be up-regulated. A total of 37
genes were up-regulated in both the rho
0 epithelial cells and breast
cancer cell lines (Table S3). The differentially expressed genes are
described to be involved in critical functions such as cellular
metabolism, apoptosis, transport, translation, DNA replication
and repair, splicing factor and cell redox homeostasis. The key
genes from each set of commonly down- and up-regulated groups
from the rho
0 epithelial cell line and breast cancer cell lines were
then validated (see Tables S2 and S3). These genes were analyzed
on a 96-well plate pre-coated with primers for quantitative real-
time PCR (RT-PCR) (custom made by Super Arrays) using the
SYBR green method. We confirmed down regulation of five
selected genes (COX6B2, MAPK5, GM2A, SOD2, and MAOA)
in rho
0 cells (Figure 1A). Among these validated genes, we
compared expression in breast cancer cell lines to normal breast
epithelial cells. As hypothesized, we found that selected genes were
also down-regulated in breast cancer cell lines (Figure 1A).
Likewise, we confirmed the up-regulation of seven genes (BID,
MRRL17, SH3PB5, MRRL49, TK1, TIMM10, and UNG) in
rho
0 cells and breast cancer cell lines (Figure 1B). We conclude
that an OXPHOS defect in rho
0 breast epithelial cells mimics the
gene expression changes of nuclear DNA-encoded mitochondrial
proteins as seen in breast cancer cell lines.
Tumor Promoting UCP2
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breast cancer
Our initial gene expression comparisons identified COX6B2 as
being down regulated in rho
0 and breast cancer cells. This is of
particular interest because COX6B2 is a subunit of cytochrome
oxidase (COX). COX is the terminal enzyme of OXPHOS that
reduces molecular oxygen to water. It is composed of 10 nuclear-
encoded and three mitochondrially encoded subunits [51]. We
measured changes in expression in all of the nuclear-encoded
members of the COX family, as well as the transcription factor
and COX master regulator, NRF1. The pattern of expression in
rho
0 cells and among breast cancer cell lines was similar in that the
genes encoding the COX protein complex, as well as the COX
master regulator NRF1, were down-regulated (Figure 2A).
UCP gene family members are up-regulated in breast
cancer
In addition to the seven up-regulated genes described above, we
found that UCP2 (uncoupling protein 2) was expressed several-
hundred-fold in rho
0 breast epithelial cells and breast cancer cell
lines. UCP2 belongs to a family of proteins that uncouples
mitochondrial respiration and ATP synthesis. To date, five
members of the UCP family have been described [53-60]. We
measured the expression of all five members of the UCP family viz.
UCP1 to 5. We confirmed the large increase in UCP2 expression
and also found a significant increase in gene expression of UCP1
and 5 in the rho
0 cells and breast cancer cell lines (Figure 2B).
Increased expression of UCP1 in primary breast tumors
UCP1 was the first identified member of the UCP family [52-
59]. We found a significant increase in UCP1 expression in breast
cancer cell lines, so we analyzed UCP1 expression in human breast
carcinomas. A TARP5 slide with several breast carcinoma sections
from different cases helped us to screen a relatively large number
of cases. Immunohistological examination showed a high expres-
sion of UCP1in 35% of breast tumors (Figure 3-IA). There was no
correlation of UCP1 expression with the tumor grade (Figure 3-
IB). We expanded UCP1 expression in ovarian carcinoma and
found 31% of them showed high expression (Figure 3-IIA). As with
breast tumors, there was no correlation between UCP1 expression
and tumor grade (Figure 3-IIB). We conclude that UCP1 is up-
regulated in breast cancer cell lines and primary breast as well as
other tumors.
UCP2 is over-expressed in primary breast tumors
The above studies identified that UCP2 expression was
increased several-hundred-fold in rho
0 breast epithelial cells and
cancer cell lines. We therefore focused our study on UCP2. We
measured UCP2 expression by real-time PCR in matched normal
and primary breast tumors and found that seven out of 10 tumors
showed a significant increase in UCP2 expression (Figure 3-III).
We used a TARP5 slide to screen a breast carcinoma for UCP2
expression. Examination of the breast-tumor sections revealed that
94% of breast carcinoma cases showed a high level of UCP2
expression (Figure 3-IVA). Our analysis revealed no correlation
between tumor grade and UCP2 expression (r=0.01) (Figure 3-
IVB). Eighty-six percent of grade 1, 100% of grade 2 and 93% of
grade 3 breast carcinomas were positive for UCP2.
UCP2 is over-expressed in multiple cancers
Since the Warburg Effect relates not only to breast cancer but is
a general phenomenon found in cancers [7], we investigated the
expression of UCP2 in other cancers. Our analyses of Oncomine
data sets revealed that UCP2 is over-expressed in ovarian, bladder,
esophageal, testicular, kidney, colorectal, lung, pancreas and
prostate cancers as well as in leukemia (Figure 3-V). As a test of
Oncomine data, we chose to validate UCP2 over-expression in
ovarian cancers (Figure 3-VI). Examination of UCP2 expression in
primary ovarian tumors indeed revealed that approximately 90%
of ovarian carcinoma cases expressed UCP2 at a very high level
(Figure 3-VIIA). No correlation was found between tumor grade
and UCP2 expression (r=0.0) (Figure 3-VIIB). Eighty percent of
grade 1, 96% of grade 2 and 78% of grade 3 ovarian tumors
strongly expressed UCP2 in more than 10% of cells (IHC score 2
and 3). We conclude that UCP2 over-expression is a general
phenomenon linked to the Warburg Effect in cancer.
Ectopic expression of UCP2 enhances tumorigenic
properties in vitro and promotes tumor growth in vivo
The above studies demonstrated an over-expression of UCP2 in
a variety of primary tumors. Therefore, in order to define the role
of UCP2 in cancer, we over-expressed UCP2 in MCF7 breast
cancer cells. The over-expression of UCP2 was confirmed by
Western blot and RT-PCR analyses (Figures 4 A and B). UCP2
ectopic expression did not result in significant changes in
expression of other UCP members (Figure 4C). The membrane
potential of UCP2 over-expressing cells was decreased by about
40% (Figure 4D). However, ATP production remained unchanged
(Figure 4E).
To test the effect of UCP2 over-expression on the tumorigenic
phenotype, we conducted in vitro assays, including cell prolifer-
ation, wound-healing, matrigel invasion and growth in soft agar.
Figure 4F demonstrates that UCP2 over-expressing cells prolifer-
ate faster than control cells. The doubling time of UCP2 over-
expressing cells was 15.2 h compared to 22.3 h for parental MCF7
cells expressing vector only. Wound-healing measurements also
showed faster cell migration in the UCP2 over-expressing cells
(Figure 4G). We measured in vitro invasion by matrigel assay. The
UCP2 over-expressing cells showed a high rate of invasion in the
matrigel as compared to the control cells (Figure 4H). Further-
more, the UCP2 over-expressing cells showed an increase in
anchorage independent growth as assayed by colony formation in
the soft agar assay (Figure 4I).
In addition to the in vitro tumorigenic phenotype, we measured
tumor growth in the mouse xenograft model. The growth of MCF-
7 and MCF-7-UCP2 orthotopic tumors in athymic nude mice is
shown in Fig. 4J. The MCF-7-UCP2 tumors grew much more
rapidly than MCF-7 tumors, with a 300% increase in MCF-7-
UCP2 tumor size at day 19 as compared to the average size at 3
days post-transplant (36 m
2), in comparison to a 125% increase for
MCF-7 tumors. Together, these studies demonstrate that over-
expression of UCP2 promotes tumorigenicity.
Genipin suppresses tumor promoting properties of UCP2
Genipin is a small molecule derived from the gardenia plant
[60]. Genipin inhibits UCP2-mediated proton leak and has been
shown to reverse obesity, as well as high glucose-induced beta
Figure 1. Changes in gene expression due to OXPHOS defect in breast epithelial cell line. (A) Down-and (B) up-regulated genes in rho
0
and breast cancer cell lines. MitoExpress chip data was validated by quantitative real time PCR (RT-PCR). Fold changes were calculated relative to the
parental MCF12A rho
+ using beta actin as control.
doi:10.1371/journal.pone.0024792.g001
Tumor Promoting UCP2
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24792Tumor Promoting UCP2
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24792cell dysfunction in isolated pancreatic islets [53]. We hypothe-
sized that genipin could suppress the tumor promoting property
of UCP2 by inhibiting its expression and function. Treatment of
MCF7 breast cancer cells with genipin decreased cell viability
( w i t ha nI C 50 of about 7 uM), whereas the genipin had little or
no affect on the proliferation of MCF12A cells (Figure 5A). This
is of interest because MCF7 cells express a significantly higher
level of UCP2 protein than MCF12A cells. Next, we tested
whether genipin’s effect was specific to UCP2 over-expression.
We measured genipin’s effect on cell proliferation and the
clonogenic survival of cells over-expressing UCP2. Our analyses
revealed a concentration-dependent effect of genipin on cell
Figure 3. Expression of UCP family members in primary tumors. (I-A) UCP1 expression in breast tumors. (I-B) UCP1 expression in relation to
breast tumor grade. (II-A) UCP1 over-expression in ovarian tumors. (II-B) UCP1 expression in relation to ovarian tumor grade. (III) UCP2 expression at
RNA level in matched normal and primary breast tumors. (IV-A) UCP2 expression at protein level in breast-tumors. (IV-B) UCP2 expression in relation
to breast tumor grade. (V) Oncomine data showing UCP2 expression in normal (N) Vs tumor (T) of bladder, esophagus, lymphocyte, testis. The p-value
is given in brackets underneath each tumor type. (VI) Oncomine data showing UCP2 over-expression in colorectal, kidney, lung, pancreatic, prostate
and ovarian tumors. (VII-A) Validation of UCP2 over-expression in primary ovarian tumors. (VII-B) Lack of correlation between UCP2 expression and
ovarian tumor grade.
doi:10.1371/journal.pone.0024792.g003
Figure 2. Gene expression profile of COX and UCP family members. Expression profile of (A) COX family members, and (B) UCP family
members in rho
0 and breast cancer cell lines relative to the parental MCF12A rho
+.
doi:10.1371/journal.pone.0024792.g002
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expressing cells were much more sensitive to genipin treatment
than control cells (Fig. 5B–C). Genipin treatment reduced
migration in the wound-healing assay and significantly inhibited
matrigel invasion of UCP2 over-expressing cells (Figures 5D, E).
Interestingly, genipin treatment led to down-regulation of UCP2.
UCP1, 3 4 and 5 were unaffected (Figure 5F). DHE oxidation (a
measure of reactive oxygen species, mainly superoxide) was also
decreased considerably with the genipin treatment (Figure 5G).
These studies suggest that genipin inhibits the tumor promoting
properties of UCP2 over-expressing cells, and this effect is
mediated by down-regulation of UCP2.
Figure 4. UCP2-induced tumor promoting properties in vitro and tumor growth in vivo. (A) Western blot analysis showing the over-
expression of UCP2 at protein level. (B) RT-PCR showing over-expression of the UCP2 at transcript level. (C) RT-PCR showing expression of UCP family
members in the UCP2 over-expressing cells. (D) TMRE fluorescence of the UCP2 over-expressing cells (E) ATP production in the UCP2 over-expressing
cells. (F) Proliferation of UCP2 over-expressing cells. (G) Wound healing in the UCP2 over-expressing cells. (H) Matrigel invasion of the UCP2 over-
expressing cells. (I) Soft agar assay of the UCP2 over-expressing cells. (J) Growth of MCF-7 parental and MCF-7-UCP2 orthotopic xenografts in athymic
nude mice. MCF-7 parental or MCF-7-UCP2 over-expressing cells were injected into the mammary fat pad two days after subcutaneous implantation
of 17b-estradiol pellets. Tumor size averaged 36 mm
2 at 3 days post-tumor cell injection in each group. N=10 mice/group.
doi:10.1371/journal.pone.0024792.g004
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Since UCP2 is over-expressed in a variety of cancers, we wished
to identify a transcriptional regulator of UCP2. An analysis of the
transcription factor binding sites of the UCP2 promoter revealed
seven putative SMAD binding sites (21179; 21378; 21445;
21506; 22005; 22401; 22738 relative to the first exon of
UCP2). In order to understand the regulatory process this
transcription factor has on UCP2, Smad4 was down-regulated
by siRNA in mouse mammary epithelial NMuMG cells and
UCP2 expression was assessed in the cells before and after
treatment with TGF-b1. Microarray analysis was performed on
duplicate samples of control and siRNA-Smad4 transfected cells.
In the control cells, TGF-b1 up-regulated UCP2 transcript levels,
whereas in the Smad4 knock-down cells, this regulation was
abrogated (Figure 6). Two other UCP homolog genes, UCP1 and
UCP3, were expressed at significantly lower levels and were not
regulated by TGF-b1 (data not shown). We conclude that TGF-b1
via a Smad-dependent mechanism regulates UCP2 expression.
Figure 5. Genipin suppression of tumor promoting properties of UCP2. (A) MTT reduction of MCF12A and MCF7 cells after 48 h of genipin
treatment. (B) MTT reduction after 48 h of genipin treatment demonstrating the increased sensitivity to genipin treatment of UCP2 over-expressing
cells. (C) Clonogenic survival of UCP2 over-expressing cells treated with different concentration of genipin. (D) Wound healing assay with different
concentration of genipin in the UCP2 over-expressing cells. (E) Matrigel invasion of MCF7 cells with different concentration of genipin in the UCP2
over-expressing cells. (F) UCPs expression after the genipin treatment in UCP2 over-expressing cells. (G) DHE oxidation of the MCF7 cells treated with
genipin (10 uM) for 1 h.
doi:10.1371/journal.pone.0024792.g005
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We took a novel strategy to identify genes responsive to
irreversible injury to OXPHOS, as described by Warburg many
years ago [9]. Our study revealed a similar pattern of gene-
expression changes in rho
0 epithelial cells, breast cancer cell lines
and primary breast tumors. Our study identified that 37 genes
were up-regulated and 30 genes were down-regulated in both rho
0
and in cancer cell lines. These genes play important roles in
transport, signal transduction, DNA replication, base excision
repair, translation, apoptosis and electron transport. Among the
up-regulated genes, UCP2’s expression was predominantly higher
in rho
0 epithelial cells, cancer cell lines and primary tumors. UCP2
belongs to a family of mitochondrial uncoupling proteins and is
involved in dissipating the proton gradient across the mitochon-
drial membrane. The UCP family contains five members [53–60].
Among the five, UCP1 functions as a thermogenic protein in
brown adipocytes [54]. UCP2 is ubiquitously expressed and
protects cells from oxidative stress [55]. UCP2 also decreases
glucose-induced hormone secretion in pancreatic islets and
neurons [56]. Several reports also suggest UCP2 and 3 regulate
fatty acid oxidation and mitochondrial calcium uniporter [57].
The other two members, UCP4 and UCP5, are expressed in a
tissue-specific manner [58]. UCP4 and 5 reduce mitochondrial
membrane potential [58]. Our study revealed a higher expression
of UCP1, 4 and 5 in rho
0 cells and cancer cell lines. However, the
expression levels of UCP1, 3, 4 and 5 (few-fold) were insignificant
when compared to UCP2 (several-hundred-fold). From this group,
we chose UCP1 for its expression in primary tumors (breast and
ovarian). UCP1 expression was increased in a small number
(,30%) of breast and ovarian tumors. In contrast, UCP2 was
over-expressed in more than 80% of breast and ovarian tumors.
Furthermore, UCP2 over-expression was found in other cancers,
including leukemia, bladder, esophagus, testicular, colorectal,
kidney, lung, pancreatic and prostate cancers. These studies
suggest that UCP2 over-expression is involved in the development
of a variety of cancer types and that UCP2 can function as a
potential diagnostic marker associated with the Warburg Effect,
described as a hallmark of cancers.
We demonstrate that UCP2 is transcriptionally regulated by
SMAD4. UCP2 is regulated both at the transcriptional and
translational levels. Sirt1 is described as a negative regulator of
UCP2 transcription via regulatory proteins such as peroxisome
proliferator-activated receptors (PPARs), forkhead transcription
factors and sterol regulatory element-binding protein-1c (SREBP-
1c) [59]. The UCP2 gene contains a short open reading frame
(ORF1) in exon 2 that potentially encodes a putative peptide of 36
amino acids and inhibits translation of UCP2 mRNA [60]. A
recent study in muscle cells suggests a microRNA (miR-133a)
mediated regulation of UCP2 [61]. UCP2 protein is highly
unstable and has a half-life of 30 min. UCP2 protein is rapidly
turned over by the cytosolic proteasome [56]. The study presented
in this paper suggests that UCP2 expression was up to 800-fold
higher in primary breast tumors when compared with paired
normal breast tissues. A similarly high level of expression was also
detected in breast cancer cell lines. It is unclear how UCP2
expression is increased to such a high level transcriptionally. At the
protein level, UCP2 expression in cancer cells was not as high,
suggesting that both transcriptional and post-transcriptional
regulation may play a role in tumorigenesis.
Very few studies have addressed the role of UCP2 in
tumorigenesis. Studies suggest that UCP2 over-expression may
protect cells from apoptosis [62]. UCP2 acts as a sensor of
mitochondrial oxidative stress and is activated by ROS. The
higher expression of UCP2 had been reported as cytoprotective by
the negative regulation of mitochondrial ROS production. UCP2
function is an important component of local feedback mechanisms
controlling the production of mitochondrial ROS [63]. UCP2
expression increases in response to the mitochondrial oxidative
stress caused by electron transport chain inhibitors (Rotenone,
antimycin A, DETC) [64]. An increase in ROS production is also
reported in UCP2 knockout mice. Over-expression of UCP2 in
colon cancer cells also inhibits ROS accumulation and apoptosis
after exposure to chemotherapeutic agents [65]. It is likely that
UCP2 over-expression also inhibits ROS accumulation in rho
0
cells, otherwise mitochondrial defect may increase ROS produc-
tion and trigger cell death.
UCP2 acts as a metabolic regulator. UCP2 was initially
identified as the gene linked to obesity and hyperinsulinemia
[38,66]. Over-expression of UCP2 in isolated islets brings down
glucose-stimulated insulin secretion [67]. Similarly, UCP2 knock-
out mice had shown increased glucose-stimulated insulin secretion
[68]. UCP2 negatively regulates insulin secretion by systematic
uncoupling, which in turns brings down the proton-motive force
and the ATP:ADP ratio in the cytosol. Leukemia cells cultured on
bone marrow-derived stromal feeder layers increase the expression
of UCP2 and decrease the entry of pyruvate into the Krebs cycle
[69]. Thus, increased UCP2 over-expression can directly contrib-
ute to the Warburg Phenotype. UCP2 is proposed to have activity
as a uniporter for pyruvate [70]. As a result, UCP2 can promote
pyruvate efflux from mitochondria and restrict glucose availability
for respiration. This may increase the high rate of glycolysis in
cancer cells [70]. Our studies suggest a novel function of UCP2.
UCP2 is thought to function by lowering mitochondrial
membrane potential to reduce oxidative stress that results from a
hyperpolarized mitochondrial membrane. The up-regulation of
UCP2 in rho
0 cells, which are grossly impaired in mitochondrial
function, suggests that the uncoupling function of UCP2 has a
limited role. In rho
0 cells the mitochondrial membrane potential is
maintained by ATP hydrolysis by the ATP synthase. The ATP
hydrolytic function of ATP synthase (Complex V) is maintained in
the absence of mtDNA-encoded proteins. Thus, bioenergetically
the uncoupling will cost more by depleting cytoplasmic ATP.
We provide evidence that UCP2 is over-expressed in a variety
of tumors derived from different organs. A recent study also
supports our findings in breast cancer [71]. To establish a cause-
and-effect relationship between UCP2 over-expression and tumor
development, we expressed UCP2 in MCF7 cells. Our studies
suggest the tumor promoting function of UCP2 in vitro and in vivo
Figure 6. SMAD4 regulation of UCP2 gene expression. UCP2 is
down-regulated by silencing Smad4 in the presence of TGFb (see text
for further detail).
doi:10.1371/journal.pone.0024792.g006
Tumor Promoting UCP2
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24792in a mouse xenograft model. UCP2, when over-expressed,
increases cell proliferation, migration and matrigel invasion and
increases anchorage-independent growth. UCP2 over-expression
also promotes growth of orthotopic tumors in vivo in athymic
nude mice.
Genipin, a metabolite derived from the gardenia plant, is shown
to be pharmacologically active against b-cell dysfunction. Genipin
also inhibits UCP2-mediated proton leak [53]. We found that
genipin treatment of UCP2 over-expressing cells decreases cell
proliferation, clonogenic survival and matrigel invasion. In
addition, genipin reduces cell proliferation of breast cancer cell
line MCF7 but not the breast epithelial MCF12A cells. This effect
of genipin was in part mediated by a decrease in mitochondrial
membrane potential and down-regulation of UCP2 gene expres-
sion. Genipin did not significantly affect the expression of other
UCPs. Our studies suggest that genipin can suppress tumor
promoting function of UCP2.
Warburg hypothesized that injury to respiration was the
underlying primary cause of tumorigenesis [14]. In his seminal
1956 article, Warburg discussed Feodor Lynen’s suggestion
reported 14 years earlier that mitochondria in cancer cells could
be uncoupled [72,73,74]. Accordingly, our studies described in this
paper suggest that mitochondrial uncoupling protein UCP2
involved in uncoupling mitochondria plays an important role in
breast, ovarian leukemia, bladder, esophagus, testicular, colorec-
tal, kidney, pancreatic, lung and prostate cancers. Collectively, our
studies suggest that i) UCP2 over-expression in tumors is a
common phenomenon; ii) UCP2 over-expression promotes tumor
development and iii) UCP2 over-expression can serve as a
promising therapeutic target for treatment of breast and many
other cancers. Furthermore, our genetic strategy revealed that
cellular adaptation of cancer cells to mitochondrial defect may
provide an opportunity to identify other gene targets that are vital
to cancer cell survival and tumor development.
Supporting Information
Table S1 The list of nuclear genes encoding the
mitochondrial proteome tiled on the MitoExpress. The
nuclear genes encoding the mitochondrial proteins were pooled
and analyzed after a series of statistical and bioinformatic analyses.
The corresponding probe sets of the genes were selected from the
NetAffx. The standard probe sets for 146 housekeeping genes as
that of human expression chip HG-U133 were included for
normalization and background correction.
(XLS)
Table S2 The list of genes that are down-regulated in
both cancer and rho
0 cell lines compared to the parental
MCF12A rho
+. The gene expression that was twofold or lower
compared to the parental MCF12A rho
+ cell line was considered
to be down regulated.
(XLS)
Table S3 The list of genes that are up-regulated in both
rho
0 and breast cancer cell lines compared to the
parental MCF12A rho
+. The gene expression that was twofold
or higher compared to the parental MCF12A rho
+ cell line was
considered to be up regulated.
(XLS)
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